Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 37% Improvement Relative Risk c19early.com/s Salehi et al. Remdesivir for COVID-19 ICU PATIENTS Favors remdesivir Favors control
Salehi, 125 patient remdesivir ICU study: 37% lower mortality [p=0.01] https://c19p.org/salehi
copied to clipboard
Risk factors of death in mechanically ventilated COVID-19 patients: a retrospective multi-center study
Salehi et al., Research Square, doi:10.21203/rs.3.rs-1362678/v1 (Preprint)
11 Mar 2022    Source   PDF   Share   Tweet
Retrospective 125 mechanically ventilated ICU patients in Iran, showing lower mortality with remdesivir treatment in unadjusted results.
[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 36.6% lower, RR 0.63, p = 0.01, treatment 17 of 40 (42.5%), control 57 of 85 (67.1%), NNT 4.1.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
Salehi et al., 11 Mar 2022, retrospective, Iran, preprint, mean age 62.0, 11 authors, study period April 2021 - September 2021.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit